Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 4,129 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neck Neoplasms Clear all

Conditions: Cervical Cancer Screening
Interventions: HPV self-sampling; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer
Interventions: Sacituzumab Govitecan-hziy (SG); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 12
States / cities: Aurora, Colorado • New Haven, Connecticut • Newark, Delaware + 8 more

Conditions: Head and Neck Cancer, Non Small Cell Lung Cancer
Interventions: Erlotinib, Dasatinib + Placebo, Erlotinib plus Dasatinib, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 15
States / cities: Tuscon, Arizona • Atherton, California • Culver City, California + 12 more

Conditions: Head and Neck Cancer, Unknown Primary Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: Pegsitacianine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
Interventions: Combination of varlilumab and nivolumab; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 19
States / cities: Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more

Conditions: Head and Neck
Interventions: Hydroxyurea, 5- Fluorouracil, Cisplatin; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 59 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Carcinoma, Squamous Cell of the Head and Neck
Interventions: REOLYSIN®, Carboplatin, Paclitaxel; Biological · Drug
Lead sponsor: Oncolytics Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: The Bronx, New York • San Antonio, Texas

Conditions: Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions: Lenvatinib; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Thyroid Cancer
Interventions: Radioactive Iodine 124; Radiation
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Nasopharyngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Malignant Posterior Tongue Neoplasm, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage II Hypopharyngeal Carcinoma AJCC v8, Stage II Laryngeal Cancer AJCC v8, Stage II Nasopharyngeal Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Oropharyngeal Squamous Cell Carcinoma
Interventions: Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration; Radiation · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Urothelial Carcinoma
Interventions: DR-0202; Drug
Lead sponsor: Dren Bio; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Denver, Colorado • Orlando, Florida • Sarasota, Florida + 7 more

Conditions: Cervical Neoplasia
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 21 Years to 100 Years · Female only
Enrollment: 131,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Oakland, California

Conditions: Cervical Cancer
Interventions: Interview; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Biospecimen Collection, Cisplatin, Computed Tomography, Diffusing Alpha-emitter Radiation Therapy, Docetaxel, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Modified Barium Swallow Study, Observation Activity, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire; Procedure · Drug · Radiation + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Head and Neck Cancers, Breast Cancer, Thoracic Cancers, Liver Cancer, Genito Urinary Cancer, Gastrointestinal Cancers
Interventions: Comparison of HyperSight CBCT imaging to conventional CBCT imaging.; Device
Lead sponsor: Varian, a Siemens Healthineers Company; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Columbus, Ohio

Conditions: Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions: Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation; Radiation · Drug · Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 4
States / cities: Gainesville, Florida • Jacksonville, Florida • Chapel Hill, North Carolina + 1 more

Conditions: Head and Neck Neoplasm, Radiotherapy
Interventions: Prescription aerobic exercise; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Petosemtamab, Investigator's Choice; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 59
States / cities: Mobile, Alabama • Prescott, Arizona • Scottsdale, Arizona + 51 more

Conditions: Head and Neck Neoplasms, Malignant Neoplasm of Vertebral Column
Interventions: Cryoablation, Biopsy; Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Head and Neck Cancer
Interventions: Optical Spectroscopy; Device
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Breast Cancer, Cervical Cancer
Interventions: Education, Navigation to clinic; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 8,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
Interventions: Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2; Biological
Lead sponsor: Gregory Daniels; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Solid Tumor, Thyroid Cancer
Interventions: Capecitabine (Xeloda), DTIC-Dome (Dacarbazine), Gleevec (Imatinib Mesylate); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

HPV Self-Sampling for Cervical Cancer Screening Among Transgender Men and Transmasculine Individuals

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma

Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH)

Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer

Simple Versus Radical Hysterectomy for Stage I Cervical Cancer

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

Feasibility Study of CBCT for IGRT in Cancer Patients

P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC

Feasibility and Safety of Aerobic Exercise for Head and Neck Cancer Patients

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

Image-guided Cryoablation of Head, Neck and Spine Tumors

Functional and Molecular Characterization of Treatment Response in Tumors in the Oral Cavity Using Optical Spectroscopy

Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma